In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123I IBZM single photon emission tomography (SPET) study

Psychopharmacology

Volumn 130, Issue 2, 1997, Pages 152-158

  Pilowsky, L S ^a,b   O'Connell, P ^a   Davies, N ^a   Busatto, G F ^a   Costa, D C ^b   Murray, R M ^a   Ell, P J ^b   Kerwin, R W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Atypical antipsychotic drugs; Clozapine; Sertindole; Single photon emission tomography

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMIDAZOLES; INDOLES; IODINE RADIOISOTOPES; MALE; NEOSTRIATUM; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030969323     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050223     Document Type: Article

References (26)

1. Barnes TRE (1989) A rating scale for drug induced akathisia. Br J Pharmacol 154:672-676
2. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 117:55-61
3. 2a ligand for single photon emission tomography (SPET): preliminary findings in humans. J Psychopharmacol 10:A39
4. 2 sites. Neuroscience 28:275-290
5. Daniel D, Scmitz P, Staser J, Sebree T, Wallin B (1995) Two open label, long term, safety studies of sertindole. Eur Neuropsychopharmacol 5:348-349
6. Deutsch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121-156
7. Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Dept of Health and Human Services publication (ADM) 76 338, Rockville, Md., pp 217-222
8. 2 and alpha 1 receptors (ex vivo radioreceptor binding studies. J Neural Transm [Gen. Sect] 89:61-69
9. Jarritt PH, Kouris K (1993) Instrumentation for brain SPET: guidelines and quantification. In: Costa DC, Morgen GF, Lassen NA (eds) New trends in nuclear neurology and psychiatry. Libbey, London, pp 36-95
10. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
11. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:103-107
12. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale. Schizophr Bull 13:261-276
13. Kerwin RW (1994) The new atypical antipsychotics. Br J Psychiatry 164:141-148
14. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: The dopamine:serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
15. 2 dopamine receptor occupancy in the living human brain. Psychopharmacology 110:265-272
16. 2 dopamine receptor occupancy after discontinuation of haloperidol decanoate. Schizophr Res 18:199
17. 2 antagonists within a series of 3-substituted 1-(4-fluorophenyl-1H-indoles. J Med Chem 35:1092-1101
18. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340:199-202
19. 123I IBZM SPET (single photon emission tomography) study. Psychol Med 23:791-799
20. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 124:148-153
21. Sanger DJ, Perrault G (1995) Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J Pharmacol Exp Ther 272:708-713
22. 123I IBZM. J Nucl Med 33:1964-1971
23. Simpson G, Angus JSW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 [suppl]: 11-19
24. Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25-33
25. Targum S, Zborowski J, Henry M, Schmitz P, Sebree T, Wallin B (1995) Efficacy and safety of sertindole in two double-blind, placebo controlled trials of schizophrenic patients. Eur Neuropsychopharmacol 5:348-349
26. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group (1996) A randomized, controlled, dose ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175